Immatics N.V. 13D

Perceptive Advisors and affiliates now hold about 7.6% of Immatics N.V., updating their Schedule 13D to reflect recent share purchases in an underwritten offering without indicating activist plans.

Perceptive Advisors LLC, together with Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman, reports beneficial ownership of 11,418,016 Ordinary Shares of Immatics N.V., representing approximately 7.6% of the outstanding shares, with the latest amendment (No. 2) reflecting a purchase by the Master Fund of 863,060 shares at $8.69 per share in the issuer’s August 26, 2026 underwritten offering; the filing does not state activist intentions and appears focused on updating ownership and recent transactions rather than seeking changes in control or governance.

Filing Facts

CIK

1809196

Ticker

IMTX

Form

13D

Source Type

fda

Accession

0001193125-26-371236

Alert Tier

7